{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:48:20Z","timestamp":1793620100059,"version":"4.5.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.canlet.2024.216965","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T06:50:52Z","timestamp":1716360652000},"page":"216965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Mitochondrial bioenergetics as a cell fate rheostat for responsive to Bcl-2 drugs: New cues for cancer chemotherapy"],"prefix":"10.1016","volume":"594","author":[{"given":"Charlotte","family":"Palominos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3944-3138","authenticated-orcid":false,"given":"Sebasti\u00e1n","family":"Fuentes-Retamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3526-0063","authenticated-orcid":false,"given":"Daniela","family":"Guzm\u00e1n-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro","family":"Araya-Maturana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-4399","authenticated-orcid":false,"given":"F\u00e9lix A.","family":"Urra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216965_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2024.216965_bib2","doi-asserted-by":"crossref","first-page":"f21","DOI":"10.1084\/jem.192.8.F21","article-title":"Cross-talk in cell death signaling","volume":"192","author":"Roy S","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2024.216965_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tibs.2013.12.006","article-title":"Many players in BCL-2 family affairs","volume":"39","author":"Moldoveanu","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.canlet.2024.216965_bib4","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/onc.2015.287","article-title":"Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer","volume":"35","author":"Merino","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2024.216965_bib5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1128\/MCB.22.1.94-104.2002","article-title":"Bcl-2 family members and functional electron transport chain regulate oxygen deprivation-induced cell death","volume":"22","author":"McClintock","year":"2002","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2024.216965_bib6","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1007\/s12094-022-03070-9","article-title":"Bcl-2 pathway inhibition in solid tumors: a review of clinical trials","volume":"25","author":"Ploumaki","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.canlet.2024.216965_bib7","series-title":"FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute Myeloid Leukemia","year":"2020"},{"key":"10.1016\/j.canlet.2024.216965_bib8","series-title":"FDA Approves Venetoclax for CLL or SLL, with or without 17 P Deletion, after One Prior Therapy","year":"2018"},{"key":"10.1016\/j.canlet.2024.216965_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metabol."},{"key":"10.1016\/j.canlet.2024.216965_bib10","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216965_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","article-title":"BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents","volume":"12","author":"Deng","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216965_bib12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.molcel.2011.10.001","article-title":"A unified model of mammalian BCL-2 protein family interactions at the mitochondria","volume":"44","author":"Llambi","year":"2011","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2024.216965_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216965_bib14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.216965_bib15","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/17460441.3.9.1123","article-title":"Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction","volume":"9","author":"Wendt","year":"2008","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.canlet.2024.216965_bib16","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/s41467-019-10363-1","article-title":"Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations","volume":"10","author":"Birkinshaw","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.216965_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/13543776.2012.644274","article-title":"Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review","volume":"22","author":"Bajwa","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.canlet.2024.216965_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-015-0224-3","article-title":"ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development","volume":"8","author":"Cang","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216965_bib19","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216965_bib20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.216965_bib21","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2024.216965_bib22","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","article-title":"Bcl-2 family proteins are essential for platelet survival","volume":"14","author":"Zhang","year":"2007","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2024.216965_bib23","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2024.216965_bib24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bmcl.2008.10.113","article-title":"Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors","volume":"19","author":"Porter","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.canlet.2024.216965_bib25","doi-asserted-by":"crossref","first-page":"20075","DOI":"10.18632\/oncotarget.24744","article-title":"S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth","volume":"9","author":"Casara","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216965_bib26","doi-asserted-by":"crossref","first-page":"19512","DOI":"10.1073\/pnas.0709443104","article-title":"Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis","volume":"104","author":"Nguyen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2024.216965_bib27","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1021\/acs.jmedchem.3c01998","article-title":"Targeting myeloid leukemia-1 in cancer therapy: advances and directions","volume":"67","author":"Deng","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2024.216965_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","article-title":"Targeting MCL-1 in cancer: current status and perspectives","volume":"14","author":"Wang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216965_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1226289","article-title":"Targeting MCL-1 protein to treat cancer: opportunities and challenges","volume":"13","author":"Tantawy","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216965_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41420-019-0199-x","article-title":"DRP-1 functions independently of mitochondrial structural perturbations to facilitate BH3 mimetic-mediated apoptosis","volume":"5","author":"Milani","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2024.216965_bib31","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216965_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.751301","article-title":"Extracellular matrix signals as drivers of mitochondrial bioenergetics and metabolic plasticity of cancer cells during metastasis","volume":"9","author":"Urra","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2024.216965_bib33","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41419-019-1648-4","article-title":"Elevated VMP1 expression in acute myeloid leukemia amplifies autophagy and is protective against venetoclax-induced apoptosis","volume":"10","author":"Folkerts","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2024.216965_bib34","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1146\/annurev.biochem.76.071905.090048","article-title":"The machines that divide and fuse mitochondria","volume":"76","author":"Hoppins","year":"2007","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.canlet.2024.216965_bib35","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1056\/NEJMra1215233","article-title":"Mitochondrial dynamics--mitochondrial fission and fusion in human diseases","volume":"369","author":"Archer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216965_bib36","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.mito.2010.08.005","article-title":"Mitochondrial fission\/fusion dynamics and apoptosis","volume":"10","author":"Sheridan","year":"2010","journal-title":"Mitochondrion"},{"key":"10.1016\/j.canlet.2024.216965_bib37","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.emboj.7601963","article-title":"Fission and selective fusion govern mitochondrial segregation and elimination by autophagy","volume":"27","author":"Twig","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2024.216965_bib38","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/cdd.2017.22","article-title":"Non-apoptotic functions of BCL-2 family proteins","volume":"24","author":"Gross","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2024.216965_bib39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tem.2015.02.004","article-title":"Regulation of mitochondrial nutrient and energy metabolism by BCL-2 family proteins","volume":"26","author":"Gimenez-Cassina","year":"2015","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.canlet.2024.216965_bib40","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.molcel.2016.02.019","article-title":"Mitochondria-judges and executioners of cell death sentences","volume":"61","author":"Bhola","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2024.216965_bib41","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.cdd.4400694","article-title":"Selective localization of Bcl-2 to the inner mitochondrial and smooth endoplasmic reticulum membranes in mammalian cells","volume":"7","author":"Gotow T","year":"2000","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2024.216965_bib42","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/cdd.2009.132","article-title":"Involvement of cytochrome c oxidase subunits Va and Vb in the regulation of cancer cell metabolism by Bcl-2","volume":"17","author":"Chen","year":"2010","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2024.216965_bib43","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/ncb2330","article-title":"Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase","volume":"13","author":"Alavian","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2024.216965_bib44","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Gui\u00e8ze","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216965_bib45","doi-asserted-by":"crossref","first-page":"eaax2863","DOI":"10.1126\/scitranslmed.aax2863","article-title":"Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response","volume":"11","author":"Sharon D","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2024.216965_bib46","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.cmet.2019.01.011","article-title":"Systematic dissection of the metabolic-apoptotic interface in AML reveals heme biosynthesis to Be a regulator of drug sensitivity","volume":"29","author":"Lin","year":"2019","journal-title":"Cell Metabol."},{"key":"10.1016\/j.canlet.2024.216965_bib47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1515\/hsz-2018-0233","article-title":"Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations","volume":"400","author":"Henz","year":"2019","journal-title":"Biol. Chem."},{"key":"10.1016\/j.canlet.2024.216965_bib48","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/s41467-020-15051-z","article-title":"Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma","volume":"11","author":"Bajpai","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.216965_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103935","article-title":"An acylhydroquinone derivative produces OXPHOS uncoupling and sensitization to BH3 mimetic ABT-199 (Venetoclax) in human promyelocytic leukemia cells","volume":"100","author":"Donoso-Bustamante","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.canlet.2024.216965_bib50","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/emboj\/20.4.661","article-title":"A reversible component of mitochondrial respiratory dysfunction in apoptosis can be rescued by exogenous cytochrome c","volume":"20","author":"Mootha Vk","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2024.216965_bib51","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1038\/emboj.2010.81","article-title":"The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation","volume":"29","author":"Ye","year":"2010","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2024.216965_bib52","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1097-2765(03)00105-9","article-title":"An integrated stress response regulates amino acid metabolism and resistance to oxidative stress","volume":"11","author":"Harding","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2024.216965_bib53","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s13238-017-0451-1","article-title":"The emerging role and targetability of the TCA cycle in cancer metabolism","volume":"9","author":"Anderson","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.canlet.2024.216965_bib54","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41419-018-0802-8","article-title":"alpha-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis","volume":"9","author":"Atlante","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2024.216965_bib55","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-019-0173-z","article-title":"Isocitrate dehydrogenase inhibitors in acute myeloid leukemia","volume":"7","author":"Liu","year":"2019","journal-title":"Biomark. Res."},{"key":"10.1016\/j.canlet.2024.216965_bib56","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1080\/10428194.2019.1602260","article-title":"Emerging drug profile: krebs cycle and cancer: IDH mutations and therapeutic implications","volume":"60","author":"Lee","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2024.216965_bib57","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1231677","article-title":"(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible","volume":"339","author":"Losman","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.canlet.2024.216965_bib58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216965_bib59","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.216965_bib60","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-018-0608-2","article-title":"BCL-2 as therapeutic target for hematological malignancies","volume":"11","author":"Perini","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216965_bib61","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41467-017-00984-9","article-title":"Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL","volume":"8","author":"Karpel-Massler","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.216965_bib62","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216965_bib63","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.canlet.2024.216965_bib64","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216965_bib65","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molmed.2010.07.002","article-title":"IDH mutations in glioma and acute myeloid leukemia","volume":"16","author":"Dang","year":"2010","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.canlet.2024.216965_bib66","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/JBM.S70716","article-title":"IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives","volume":"7","author":"Mondesir","year":"2016","journal-title":"J Blood Med"},{"key":"10.1016\/j.canlet.2024.216965_bib67","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1146\/annurev-biochem-061516-044732","article-title":"Isocitrate dehydrogenase mutation and (R)-2-Hydroxyglutarate: from basic discovery to therapeutics development","volume":"86","author":"Dang","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.canlet.2024.216965_bib68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41375-019-0485-x","article-title":"Genetic characterization of ABT-199 sensitivity in human AML","volume":"34","author":"Bisaillon","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216965_bib69","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216965_bib70","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ajh.25146","article-title":"Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2024.216965_bib71","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei Ah","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216965_bib72","series-title":"FDA Granted Regular Approval to Enasidenib for the Treatment of Relapsed or Refractory AML","year":"2017"},{"key":"10.1016\/j.canlet.2024.216965_bib73","article-title":"Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2\/R140Q","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2024.216965_bib74","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1182\/blood-2018-99-119688","article-title":"Combination of Enasidenib and venetoclax shows superior anti-leukemic activity against IDH2 mutated AML in patient-derived xenograft models","volume":"132","author":"Cathelin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216965_bib75","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","article-title":"Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers","volume":"9","author":"Popovici-Muller","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.canlet.2024.216965_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10060187","article-title":"Evolving treatment strategies for elderly leukemia patients with IDH mutations","volume":"10","author":"Buege","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.216965_bib77","doi-asserted-by":"crossref","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A phase Ib\/II study of Ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated myeloid malignancies","volume":"4","author":"Lachowiez Ca","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216965_bib78","doi-asserted-by":"crossref","first-page":"8186","DOI":"10.1096\/fj.201802723R","article-title":"Statin-dependent modulation of mitochondrial metabolism in cancer cells is independent of cholesterol content","volume":"33","author":"Christie","year":"2019","journal-title":"Faseb. J."},{"key":"10.1016\/j.canlet.2024.216965_bib79","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3324\/haematol.2018.204701","article-title":"Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies","volume":"104","author":"Al-Zebeeby","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2024.216965_bib80","article-title":"ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future","volume":"9","author":"Rozeboom B","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216965_bib81","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1128\/MCB.20.8.2890-2901.2000","article-title":"17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence","volume":"20","author":"Perillo B","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2024.216965_bib82","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2159-8290.CD-18-1151","article-title":"A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer","volume":"9","author":"Lok","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216965_bib83","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/1078-0432.CCR-21-3811","article-title":"VERONICA: randomized phase II study of fulvestrant and venetoclax in ER-positive metastatic breast cancer post-CDK4\/6 inhibitors - efficacy, safety, and biomarker results","volume":"28","author":"Lindeman","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216965_bib84","doi-asserted-by":"crossref","first-page":"26046","DOI":"10.18632\/oncotarget.25433","article-title":"BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucose","volume":"9","author":"Lucantoni","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216965_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/antiox12081597","article-title":"A new quinone-based inhibitor of mitochondrial complex I in D-conformation, producing invasion reduction and sensitization to venetoclax in breast cancer cells","volume":"12","author":"Monroy-C\u00e1rdenas","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.canlet.2024.216965_bib86","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1042\/BJ20140620","article-title":"Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria","volume":"462","author":"Bridges","year":"2014","journal-title":"Biochem. J."},{"key":"10.1016\/j.canlet.2024.216965_bib87","doi-asserted-by":"crossref","first-page":"21166","DOI":"10.18632\/oncotarget.24989","article-title":"Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells","volume":"9","author":"Chukkapalli","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216965_bib88","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.7150\/jca.60208","article-title":"Metformin exerts a synergistic effect with venetoclax by downregulating Mcl-1 protein in acute myeloid leukemia","volume":"12","author":"Zhou","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.canlet.2024.216965_bib89","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/bjh.18968","article-title":"Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-CHOP pathway","volume":"202","author":"Hua","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2024.216965_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15051533","article-title":"Pictolysin-III, a hemorrhagic type-III metalloproteinase isolated from Bothrops pictus (serpentes: viperidae) venom, reduces mitochondrial respiration and induces cytokine secretion in epithelial and stromal cell lines","volume":"15","author":"Vivas-Ruiz","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.canlet.2024.216965_bib91","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2015-01-621870","article-title":"Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition","volume":"126","author":"Jacque","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216965_bib92","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/2643-3230.BCD-23-0014","article-title":"Clinical correlates of venetoclax-based combination sensitivities to augment acute myeloid leukemia therapy","volume":"4","author":"Eide","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216965_bib93","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216965_bib94","series-title":"PubChem Compound Summary for CID 46228957, Abt737;abt 737","year":"2024"},{"key":"10.1016\/j.canlet.2024.216965_bib95","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/pbc.21433","article-title":"Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program","volume":"50","author":"Lock","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.canlet.2024.216965_bib96","series-title":"PubChem Compound Summary for CID 24978538, Navitoclax","year":"2024"},{"key":"10.1016\/j.canlet.2024.216965_bib97","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.216965_bib98","series-title":"PubChem Compound Summary for CID 49846579, Venetoclax","year":"2024"},{"key":"10.1016\/j.canlet.2024.216965_bib99","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1021\/acsmedchemlett.9b00568","article-title":"Discovery of A-1331852, a first-in-class, potent, and orally-bioavailable BCL-XL inhibitor","volume":"11","author":"Wang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.canlet.2024.216965_bib100","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1021\/ml5001867","article-title":"Discovery of a potent and selective BCL-XL inhibitor with in vivo activity","author":"Tao","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.canlet.2024.216965_bib101","doi-asserted-by":"crossref","first-page":"279ra240","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2024.216965_bib102","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-07-1919","article-title":"Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)","volume":"68","author":"Konopleva","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216965_bib103","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/CE.S42568","article-title":"An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies","volume":"8","author":"Goard","year":"2013","journal-title":"Core Evid."},{"key":"10.1016\/j.canlet.2024.216965_bib104","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/blood-2011-11-391037","article-title":"Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma","volume":"119","author":"Oki","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216965_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.561","article-title":"Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)","volume":"6","author":"Leverson","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2024.216965_bib106","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.216965_bib107","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216965_bib108","unstructured":"A.E. Tron, M.A. Belmonte, A. Adam, B.M. Aquila, L.H. Boise, E. Chiarparin, J. Cidado, K.J. Embrey, E. Gangl, F.D. Gibbons, G.A.-O. Gregory, D. Hargreaves, J.A. Hendricks, J.A.-O. Johannes, R.W. Johnstone, S.L. Kazmirski, J.G. Kettle, M.A.-O. Lamb, S.M. Matulis, A.K. Nooka, M.J. Packer, B. Peng, P.B. Rawlins, D.W. Robbins, A.G. Schuller, N. Su, W.A.-O. Yang, Q. Ye, X. Zheng, J.P. Secrist, E.A. Clark, D.M. Wilson, S.E. Fawell, A.A.-O. Hird, Discovery of Mcl-1-specific Inhibitor AZD5991 and Preclinical Activity in Multiple Myeloma and Acute Myeloid Leukemia.."},{"key":"10.1016\/j.canlet.2024.216965_bib109","series-title":"PubChem Compound Summary for CID 131634760, Unii-E3T5xxy9HX","year":"2024"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524003586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524003586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T13:59:47Z","timestamp":1717250387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524003586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":109,"alternative-id":["S0304383524003586"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216965","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitochondrial bioenergetics as a cell fate rheostat for responsive to Bcl-2 drugs: New cues for cancer chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216965","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"216965"}}